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C L I N I C A L C O M M E N TA R Y
Modify risk factors not only for stroke 
but overall cardiovascular disease
No studies look specifically at patients
already on aspirin, so we must extrapolate
from other prevention trials how to best
manage them. If aspirin therapy has failed,
the choice of either aspirin and dipyridamole
or clopidogrel should take into account cost,
availability, side-effect profile, and a patient’s
comorbidities and preferences. There are no
clear benefits of one over another. While the
combination of aspirin and clopidogrel has
shown benefit in acute coronary syndromes,
what’s good for the heart may not necessari-
ly be good for the brain. The MATCH study
showed potential increases in bleeding from
combination therapy; we should avoid the
use of this combination for prophylaxis.
As primary care physicians concerned
with our patients’ overall health, we must
aggressively modify those factors that put
patients at risk not only for recurrent stroke
or TIAs but overall cardiovascular disease.
This means controlling hypertension,
promoting smoking cessation and a healthy
lifestyle, improving lipid parameters, and
appropriate screening and management 
of diabetes.
Robert Oh, MD
University of Washington
Alternative antiplatelet therapy for stroke 
prevention is indicated for patients who
experience transient ischemic attacks (TIAs)
while on aspirin therapy (strength of 
recommendation [SOR]: A, based on 1 meta-
analysis and 1 randomized controlled trial).
The combination of aspirin and extended-
release dipyridamole reduces the risk of
stroke following a TIA (SOR: A). Thieno-
pyridines (eg, clopidogrel and ticlopidine) are
an alternative for patients at high risk for a
cardioembolic event. Ticlopidine reduces the
risk of stroke following TIA, specifically 
showing benefit for patients previously on
aspirin (SOR: A). Clopidogrel has not shown
significant reduction in reoccurrence of
stroke and has not been studied for patients
with a previous TIA. Aspirin and a thieno-
pyridine do not provide significant additional
reduction in secondary strokes (SOR: A).
z Evidence summary
Patients who experience TIAs are at high
risk for stroke and need adequate preven-
tative therapies. A meta-analysis evaluated
158 randomized trials involving primary
and secondary prevention of stroke, con-
cluding that antiplatelet therapy results in
a 30% reduction in occurrence of ischemic
stroke (95% confidence interval [CI],
24–35; P<.0001).1 Data that evaluate the
antiplatelet efficacy following a TIA while
on aspirin therapy are limited. 
Combination aspirin and dipyridamole
(Aggrenox) therapy reduces the risk of sec-
ondary stroke. Several randomized con-
trolled trials (RCTs) that evaluated this
combination for prevention of stroke
included patients who had TIAs. Although
the combination reduced the occurrence of
a subsequent stroke, the difference was not
significant compared with aspirin alone,
possibly due to the use of high-dose aspirin
in the comparison group.2,3 A large-scale
RCT including patients with previous
stroke or TIA concluded that the combina-
tion of aspirin and extended-release dipyri-
damole reduced the occurrence of stroke by
23% (P<.001) compared with aspirin
(number needed to treat [NNT]=35; 95%
CI, 20–130).4 In this trial, patients with a
prior TIA comprised only one quarter of
the patients studied.4 Subgroup analyses of
patients on aspirin prior to experiencing a
TIA have not been reported.
Thienopyridines may be considered
for secondary stroke prevention for
patients at high risk for a cardioembolic
event. An RCT studying secondary preven-
tion of stroke, in which 50% of the study
population experienced a TIA as their
qualifying event, concluded that ticlopi-
dine (Ticlid) reduced the risk of stroke by
21% (95% CI, 0.04–0.38; P=.024).5
Subgroup analysis indicated that ticlopi-
dine provided superior benefit for patients
on aspirin or anticoagulant therapy at the
time of their qualifying event.6 Unlike ticlo-
pidine, clopidogrel (Plavix) does not have
significant hematologic side effects. An
RCT comparing clopidogrel with aspirin
found a nonsignificant risk reduction of
0.3% (95% CI, –0.03 to 0.9; P=.26) in
occurrence of stroke when compared with
aspirin for patients with previous stroke,
myocardial infarction, or peripheral arteri-
al disease. A 0.9% absolute reduction in
combined risk of cardioembolic events was
reported for patients randomized to clopi-
dogrel (NNT=111; 95% CI, 57–2454;
P=.043), but patients with TIA were
excluded from the study population.7
A large-scale RCT concluded that the
combination of clopidogrel and aspirin did
not provide additional benefit in reducing
a combined endpoint of cardioembolic
events in comparison with aspirin alone
for patients with prior stroke or TIA. The
combination resulted in a significantly
greater number of life-threatening and
major bleeding complications.8
Recommendations from others
The American Heart Association addresses
the lack of evidence in treating patients who
experience a TIA while on aspirin therapy.
They recommend therapy be individualized
for each patient to receive either the combi-
nation of extended-release dipyridamole
and aspirin or clopidogrel daily for second-
ary prevention.9 Clopidogrel 75 mg daily is
recommended over ticlopidine 250 mg
twice daily due to its favorable safety pro-
file.10 Similarly, the American College of
Chest Physicians recommends use of
dipyridamole and aspirin 200/25 mg twice
daily or clopidogrel 75 mg daily.11
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has failed, the
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cost, side effects,
and patient 
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